Thomas Langmann

Title: Thomas Langmann: Innovator in Neurodegenerative Disease Treatment

Introduction

Thomas Langmann is a notable inventor based in Frechen, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of neurodegenerative and neuroinflammatory diseases. His innovative work has the potential to impact the lives of many individuals suffering from these conditions.

Latest Patents

Langmann holds a patent for a novel polysialic acid and its use in treating neurodegenerative and neuroinflammatory diseases. The patent describes a branched or unbranched free or glycosidically bound polysialic acid, represented by the general formula (1): poly-(α(2→8 or 2→9)Neu5Ac)(1). In this formula, Neu5Ac refers to N-acetylneuraminic acid, and 'n' is an integer ranging from 14 to 26. This invention also includes a polysaccharide composition comprising the polysialic acid and its application as a medicament, particularly for the therapeutic and prophylactic treatment of degenerative, demyelinating, and inflammatory diseases of the central nervous system, as well as degenerative or inflammatory retinal diseases. Langmann's patent represents a significant advancement in medical science.

Career Highlights

Throughout his career, Thomas Langmann has worked with prestigious institutions, including the Rheinische Friedrich-Wilhelms-Universität Bonn and Universität zu Köln. His research and innovations have garnered attention in the scientific community, establishing him as a key figure in his field.

Collaborations

Langmann has collaborated with notable colleagues such as Harald Neumann and Jens Kopatz. These partnerships have contributed to the advancement of his research and the development of his patented technologies.

Conclusion

Thomas Langmann's contributions to the field of neurodegenerative disease treatment through his innovative patent highlight his role as a significant inventor. His work continues to pave the way for future advancements in medical therapies.